Cargando…

Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimer’s Disease

BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer’s disease (AD) who would benefit most from long-term galantamine therapy. METHODS: Data were analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kavanagh, S, Howe, I, Brashear, H R, Wang, D, Baelen, B Van, Todd, M, Schwalen, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers Ltd 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182415/ https://www.ncbi.nlm.nih.gov/pubmed/21222607 http://dx.doi.org/10.2174/156720511795256044

Ejemplares similares

Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease
por: Baakman, Anne Catrien, et al.
Publicado: (2022)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease
por: Hager, Klaus, et al.
Publicado: (2014)

The Effects of Galantamine Treatment on Attention and Its Relationship with Cognition and Activities of Daily Living in Patients with Mild to Moderate Alzheimer's Disease
por: Lee, Jae-Hong, et al.
Publicado: (2015)

Economic and Clinical Benefits of Galantamine in the Treatment of Mild to Moderate Alzheimer's Disease in a Korean Population: A 52-Week Prospective Study
por: Suh, Guk-Hee, et al.
Publicado: (2008)

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease
por: Delnomdedieu, Marielle, et al.
Publicado: (2016)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study
por: Hager, Klaus, et al.
Publicado: (2016)

Mild cognitive disorder and depression: treatment with combination of galantamine and escitalopram
por: Zarra, Julio, et al.
Publicado: (2010)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children
por: Papi, Alberto, et al.
Publicado: (2011)

Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting
por: Nakagawa, Ryoko, et al.
Publicado: (2017)

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial
por: Prins, Niels D, et al.
Publicado: (2014)

Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
por: Hüll, Michael, et al.
Publicado: (2017)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Hansen, Richard A, et al.
Publicado: (2008)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
por: Li, Dan-Dan, et al.
Publicado: (2019)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

Long-term Prognosis of Mild to Moderate Aortic Stenosis and Coronary Artery Disease
por: Lee, Wonjae, et al.
Publicado: (2021)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

The Role of Individual Characteristics in Predicting Short- and Long-Term Cognitive and Psychological Benefits of Cognitive Stimulation Therapy for Mild-to-Moderate Dementia
por: Carbone, Elena, et al.
Publicado: (2022)

The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease
por: Barker, Roger A, et al.
Publicado: (2013)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

Investigation of the Factors Affecting Quality of Life in Patients with Mild to Moderate Alzheimer’s Disease in Terms of Patients and Caregivers
por: Felekoğlu, Elvan, et al.
Publicado: (2021)

Long-Term Impairment of Sound Processing in the Auditory Midbrain by Daily Short-Term Exposure to Moderate Noise
por: Cheng, Liang, et al.
Publicado: (2017)

Short-Term Longitudinal Study of Central Auditory Function in Alzheimer's Disease and Mild Cognitive Impairment
por: Idrizbegovic, Esma, et al.
Publicado: (2013)

Thalamic atrophy and dysfunction in patients with mild-to-moderate traumatic diffuse axonal injury: a short-term and mid-term MRI study
por: Wu, Lin, et al.
Publicado: (2018)

Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination
por: Jalili, Ahmad, et al.
Publicado: (2022)

Emollients “Plus” are Beneficial in Both the Short and Long Term in Mild Atopic Dermatitis
por: Cestari, Silmara, et al.
Publicado: (2023)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j2dslvh35mh9hvfl5jcpr61m36